石药集团宣布,该集团开发的1类新药双特异性融合蛋白药物JMT108已获美国食品药品监督管理局(FDA)批准,可在美国开展临床试验。该产品已于2025年3月获得中国国家药品监督管理局批准在中国开展临床试验。
(文章来源:人民财讯)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.